AstraZeneca: 79% effective against corona ‘symptoms’

This news has been read 26766 times!

KUWAIT CITY, March 24: The AstraZeneca Company has said according to the analysis it has positive high-level results from an interim of “American AstraZeneca Phase III AZD1222” trials. The company said in a letter to Kuwait’s Ministry of Health according to the data the vaccine has shown statistically significant effectiveness of 79% in preventing symptoms of ‘COVID-19’, in addition to 100% in preventing severe diseases and hospitalization.

The company sources added the third phase trial in the United States led by AstraZeneca includes two doses that were given 4 weeks apart, as the effectiveness of the vaccine was consistent across race and age, noting that the effectiveness of the vaccine was 80% in participants aged 65 years and over, who represented about 20% of the recipients.

The company explained that the interim safety and efficacy analysis was based on 32,449 recipients across 88 trial centers in the United States, Peru and Chile, which recorded 141 cases of symptoms of ‘COVID-19, the vaccine was well tolerated, and the Data Safety Monitoring Committee (DSMB) did not identify any safety concerns related to the vaccine.

The company noted that during the interim analysis, the DSMB also conducted a specific review of thromboembolic events through data from the American experiments, as the DSMB found no increased risk of thrombosis or events characterized by thrombosis among 21,583 participants receiving at least one dose of the vaccine, pointing out that the specific search for cerebral venous sinus thrombosis (CVST) did not find any events in this trial.

This news has been read 26766 times!